BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 31, 2005
 |  BioCentury  |  Product Development

Aurora, the crowd

Aurora, the crowd

Aurora, the crowd
The two disclosed aurora kinase inhibitor partnerships have relatively similar terms, and therefore could serve as a benchmark for other companies considering deals for their unpartnered compounds. The two deals for preclinical aurora inhibitors fetched $20-$25 million up front and $130-$135 million in milestones for the first compound. Rigel Pharmaceuticals Inc. (RIGL,...

Read the full 291 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >